Inhibition and induction of CYP enzymes in humans: an update

J Hakkola, J Hukkanen, M Turpeinen, O Pelkonen - Archives of Toxicology, 2020 - Springer
The cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing
the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies …

[HTML][HTML] Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development

Y Lai, X Chu, L Di, W Gao, Y Guo, X Liu, C Lu… - … Pharmaceutica Sinica B, 2022 - Elsevier
Drug metabolism and pharmacokinetics (DMPK) is an important branch of pharmaceutical
sciences. The nature of ADME (absorption, distribution, metabolism, excretion) and PK …

SuperCYPsPred—a web server for the prediction of cytochrome activity

P Banerjee, M Dunkel, E Kemmler… - Nucleic acids …, 2020 - academic.oup.com
Abstract Cytochrome P450 enzymes (CYPs)-mediated drug metabolism influences drug
pharmacokinetics and results in adverse outcomes in patients through drug–drug …

Predicting clinical effects of CYP3A4 modulators on abemaciclib and active metabolites exposure using physiologically based pharmacokinetic modeling

MM Posada, BL Morse, PK Turner… - The Journal of …, 2020 - Wiley Online Library
Abemaciclib, a selective inhibitor of cyclin‐dependent kinases 4 and 6, is metabolized
mainly by cytochrome P450 (CYP) 3A4. Clinical studies were performed to assess the …

Absence of ethnic difference on single‐dose pharmacokinetics of rivoceranib between healthy male Caucasian, Japanese, and Chinese subjects

M Sachar, CH Park, L Pesco‐Koplowitz… - Fundamental & …, 2021 - Wiley Online Library
Rivoceranib (known in China as apatinib) is a selective vascular endothelial growth factor
receptor‐2 (VEGFR‐2) tyrosine kinase inhibitor which inhibits angiogenesis in solid tumors …

Predicting the drug–drug interaction mediated by CYP3A4 inhibition: method development and performance evaluation

H Ren, Y Sai, T Chen, C Zhang, L Tang, C Yang - The AAPS Journal, 2022 - Springer
The prediction of drug–drug interactions (DDIs) plays critical roles for the estimation of DDI
risk caused by inhibition of CYP3A4. The aim of this paper is to develop a physiologically …

Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders

K Sakaguchi, T Naito, K Hoshikawa, Y Miyadera… - Drug Metabolism and …, 2024 - Elsevier
Factors that determine clinical responses to vonoprazan remain unknown. This study aimed
to characterize plasma vonoprazan and CYP3A activity using its endogenous marker and …

Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic …

S Li, L Xie, L Yang, L Jiang, Y Yang, H Zhi, X Liu… - Pharmaceutical …, 2023 - Springer
Purpose To develop a whole physiologically based pharmacokinetic-pharmacodynamic
(PBPK-PD) model to describe the pharmacokinetics and anti-gastric acid secretion of …

Extrapolation of physiologically based pharmacokinetic model for tacrolimus from renal to liver transplant patients

K Itohara, I Yano, S Nakagawa, A Yonezawa… - Drug Metabolism and …, 2022 - Elsevier
Physiologically based pharmacokinetic (PBPK) modeling is useful for evaluating differences
in drug exposure among special populations, but it has not yet been employed to evaluate …

Abundance and associated variations of cytochrome P450 drug-metabolizing enzymes in the liver of East asian adults: a meta-analysis

XX An, Y Yu, GF Li, G Yu - European Journal of Drug Metabolism and …, 2021 - Springer
Abstract Background Cytochrome P450 (CYP) enzymes are one of the main sources of
variability in drug metabolic clearance. Information on their abundance levels is therefore …